Condition: Advanced Non-small Cell Lung Cancer · EGFR Mutation · HER2 Mutation · Sponsor: Bayer
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body. Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are proteins that help cells to grow and divide. A damage (also called mutation) to the building plans (genes) for these proteins in cancer cells leads to a production of abnormal EGFR and/or HER2. These abnormal proteins drive the growth and the spread of the cancer. Several EGFR and/or HER2 mutations exist in the cancer cells. The study treatment, sevabertinib (BAY2927088), is expected to block the mutated EGFR and HER2 proteins which may stop the spread of NSCLC. The main purpose of this study is to learn: Escalation, Backfill, and Expansion Part: * How safe is BAY2927088 for the participants? * What is the highest dose of BAY2927088 that can be tolerated (maximum tolerated dose) by or given to (maximum administered dose) the participants? * How does BAY2927088 move into, through, and out of the bodies of the participants? For this, the researchers will measure the followings: * The number of participants with medical problems, also called adverse events and serious adverse events, and their severity * The number of participants who discontinue study treatment due to an adverse event. * The highest dose of BAY2927088 that the participants can take without having adverse events (m…
This description comes directly from the study's public registry record.
Bayer Clinical Trials Contact · (+)1-888-84 22937 · clinical-trials-contact@bayer.com
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center at Banner Gateway Medical Center | Gilbert, Arizona, United States | Completed |
| City of Hope - Duarte Cancer Center | Duarte, California, United States | Recruiting |
| Emory Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| The Center for Cancer and Blood Disorders | Bethesda, Maryland, United States | Terminated |
| Dana-Farber Cancer Institute - Oncology Department | Boston, Massachusetts, United States | Completed |
| Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit | Detroit, Michigan, United States | Active Not Recruiting |
| Roswell Park Comprehensive Cancer Center | Buffalo, New York, United States | Withdrawn |
| NYU Langone Hospital - Long Island - Urology | Mineola, New York, United States | Not Yet Recruiting |
| Tennessee Oncology - Nashville Centennial Clinic | Nashville, Tennessee, United States | Completed |
| The University of Texas MD Anderson Cancer Center - Texas Medical Center | Houston, Texas, United States | Recruiting |
| Virginia Cancer Specialists, PC - Fairfax | Fairfax, Washington, United States | Active Not Recruiting |
| UZ Leuven Gasthuisberg - Pneumology Department | Leuven, Flemish Brabant, Belgium | Recruiting |
+ 82 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05099172